Two-year clinical outcomes of patients treated with the dual-therapy stent in a 1000 patient all-comers registry.

ABSTRACT:

Objective

The dual-therapy stent combines an abluminal biodegradable drug-eluting coating, with a 'pro-healing' luminal layer. This bioengineered layer attracts circulating endothelial progenitor cells that can differentiate into normal endothelium. Rapid endothelialisation of the stent might allow safe short dual antiplatelet therapy. We aim to assess clinical outcomes in patients treated with this novel device at 2-year follow-up.

Methods

A total of 1000 patients were included in the REMEDEE Registry to evaluate clinical outcomes after treatment with the dual-therapy stent. This prospective, multicentre, European registry included all-comers patients, which resulted in a high-risk patient population. Target lesion failure (TLF), a combined endpoint consisting of cardiac de

SUBMITTER: Kalkman DN 

PROVIDER: S-EPMC5515182 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature